Role of new anticoagulants for the prevention of venous thromboembolism after major orthopaedic surgery and in hospitalised acutely ill medical patients. by Ageno W et al.
Review Article
Role of new anticoagulants for the prevention of venous
thromboembolism after major orthopaedic surgery and in hospitalised
acutely ill medical patients
Walter Ageno
1
; Alex C. Spyropoulos
2
; Alexander G.G. Turpie
3
1
University of Insubria-Ospedale di Circolo, Varese, Italy;
2
University of Rochester Medical Center, Rochester, New York, USA;
3
McMaster University, Hamilton, Ontario, Canada
Summary
Anticoagulation therapy for the prevention of venous thromboembolic
events (VTE) is indicated in patients after major orthopaedic surgery
and in hospitalised acutely ill medical patients who have a high or mod-
erate risk of VTE, respectively. Clinical trials have clearly demonstrated
that short-term anticoagulation reduces the risk of VTE in these patient
groups and that longer-term anticoagulation is beneficial for some in-
dications. Evidence-based guidelines for thromboprophylaxis have
been developed based on these studies. However, despite these guide-
lines, thromboprophylaxis is still underused, or used suboptimally, in
many patients. This is, in part, because of the limitations of traditional
anticoagulants such as unfractionated heparin, low-molecular-weight
heparin, synthetic pentasaccharides, and vitamin K antagonists. Newer
oral anticoagulants, such as rivaroxaban, apixaban, and dabigatran et-
exilate, have certain advantages over traditional agents. They can be
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administered orally at a fixed dose without routine coagulation moni-
toring and have minimal food and drug interactions. These character-
istics may result in better adherence to guidelines and improved patient
outcomes. This review provides an overview of phase III clinical trial
data for these newer anticoagulants in major orthopaedic surgery and
in hospitalised acutely ill medical patients, and discusses their potential
for extended use in the post-hospital discharge setting.All three newer
oral anticoagulants are approved in many countries for the prevention
of VTE after hip replacement or knee replacement surgery in adult pa-
tients, and it is likely that these drugs will contribute considerably to-
wards reducing the substantial healthcare burden associated withVTE.
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Introduction
Venous thromboembolism (VTE), which comprises deep-vein
thrombosis (DVT) and pulmonary embolism (PE), causes con-
siderable morbidity and mortality and places a substantial burden
on healthcare resources (1, 2). Patients who undergo major ortho-
paedic surgery, which includes total knee replacement (TKR), total
hip replacement (THR), and hip fracture surgery (HFS), are at a
high risk of VTE. In this patient group, the rate of asymptomatic,
objectively confirmed DVT is 40–60% without thromboprophyla-
xis. In comparison, patients admitted for an acute medical illness
(such as infection, respiratory failure, cardiovascular disease, or
neurological disease) are at a moderate risk of VTE; the rate of
DVT is 10–20% (3). Oncology patients have an increased risk of
new or recurrent VTE when compared with patients who do not
have cancer. The risk of VTE in patients with cancer is increased by
three- to five-fold for those who undergo surgery and by 6.5-fold
for those receiving chemotherapy (4, 5).
The benefits of thromboprophylaxis after major orthopaedic
surgery are well established (3), and clinical trials have shown that
the use of anticoagulants reduces the risk of VTE in hospitalised
acutely ill medical patients (6–10). Identification of patients at risk
of VTE will facilitate the administration of appropriate thrombo-
prophylaxis and reduce the incidence of VTE and its compli-
cations. VTE risk factors can be patient related (e.g. age, obesity,
hormonal therapy, cancer, previous VTE, molecular thrombophi-
lia, chronic venous insufficiency, and prolonged immobility or bed
rest >3 days) or treatment related (e.g. type and length of surgery,
and type of anaesthesia) (11–13). VTE risk factors are generally
cumulative (14), and as many as 80% of patients hospitalised for
DVT have three or more predisposing factors (15). Risk assessment
models have been recently validated in clinical trials to predict the
risk of VTE for hospitalised acutely ill medical patients (16, 17) or
cancer patients (18); however, these are not yet routinely used.
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Several evidence-based guidelines for VTE prevention exist. For
patients undergoing THR, TKR, or HFS, the American College of
Chest Physicians (ACCP) guidelines recommend low-molecular-
weight heparin (LMWH), fondaparinux, or a vitamin K antagon-
ist (VKA); unfractionated heparin (UFH) is also recommended for
HFS. Thromboprophylaxis is recommended for up to 35 days after
THR and HFS and for at least 10 days after TKR, and there is some
evidence that continuing prophylaxis for up to 35 days after TKR is
beneficial (3). The current American Academy of Orthopaedic
Surgeons (AAOS) guidelines differ from those of the ACCP in that
they do not recognise DVT as a critical outcome (19). The AAOS
guidelines do not recommend specific anticoagulants for VTE pro-
phylaxis in patients undergoing TKR or THR; the choice of pro-
phylaxis and duration of treatment depends on the perceived
bleeding risk of each individual patient (19). For VTE prophylaxis
in hospitalised acutely ill medical patients with risk factors for
VTE, the ACCP guidelines recommend low-dose UFH, LMWH, or
fondaparinux. However, there are no recommendations for the op-
timal duration of thromboprophylaxis for acutely ill medical pa-
tients (20). Mechanical methods (graduated compression stock-
ings and intermittent pneumatic compression) are recommended
primarily for surgical and non-surgical patients with contraindi-
cations to anticoagulant thromboprophylaxis (3).
In patients with cancer who are immobilised and have an acute
medical illness, low-dose UFH, LMWH, or fondaparinux are rec-
ommended by several organisations, including the ACCP, Inter-
national Union of Angiology, and American Society of Clinical
Oncology (ASCO) (3, 21, 22). There is little guidance on the opti-
mal duration of thromboprophylaxis in patients with cancer, al-
though the ASCO guidelines recommend continuing thrombo-
prophylaxis for the duration of hospital stay or until the patient is
ambulatory. OutpatientVTE prophylaxis is recommended only for
patients receiving highly thrombogenic thalidomide- or lenalido-
mide-based combination chemotherapy regimens.
Traditional anticoagulants have limitations: UFH, LMWH, and
fondaparinux are administered parenterally; VKAs require routine
coagulation monitoring for prophylaxis and have numerous food
and drug interactions (23). Newer oral anticoagulants, such as the
direct factor Xa inhibitors rivaroxaban and apixaban, and the
thrombin inhibitor dabigatran etexilate, are being developed and
have the potential to address some of these limitations. This review
will provide an overview of the phase III clinical trial data for these
newer anticoagulants in major orthopaedic surgery and in hospi-
talised acutely ill medical patients, and discuss their potential for
extended use in the post-hospital discharge setting. The phar-
macology of these agents and VTE prevention studies in patients
undergoing THR or TKR have been reviewed previously by Ufer
(24).
New oral anticoagulants
The pharmacological profiles of the newer oral anticoagulants ri-
varoxaban, apixaban, and dabigatran etexilate are summarised in
Table 1 (25–27). These three agents have been studied in phase
III trials for VTE prevention after THR and TKR surgery (Table
2) (28–40). Rivaroxaban 10 mg once daily (od) (25, 41) and dabi-
gatran etexilate 220 mg od (27, 41) are widely approved for the pri-
mary prevention of VTE in adults after elective hip or knee replace-
ment surgery.Apixaban 2.5 mg twice daily (bid) has been approved
recently for VTE prevention in this patient group in the EU (26).
For VTE prevention in acutely ill medical patients, rivaroxaban
and apixaban have recently completed phase III trials (42, 43)
There are currently no phase III trials for dabigatran etexilate in
this population.
VTE prevention after major orthopaedic
surgery
Anticoagulation therapy is indicated for all patients undergoing
TKR or THR, with the aim to achieve an optimal balance between
VTE prevention and the risk of bleeding (44). For both types of
procedure, post-surgery hospital stays are typically 3–10 days (45).
There is a continued risk of VTE after hospital discharge; therefore,
post-discharge administration of effective, well-tolerated, and
convenient anticoagulants would be beneficial for patients.
Rivaroxaban was evaluated in four phase III studies: RECORD1
and RECORD2 (THR studies), and RECORD3 and RECORD4
(TKR studies) (28–31). RECORD1 compared rivaroxaban 10 mg
od with the LMWH enoxaparin 40 mg od for 31–39 days (28).
RECORD2 compared rivaroxaban 10 mg od for 31–39 days with
enoxaparin 40 mg od for 10–14 days followed by placebo (29).
RECORD3 and RECORD4 compared rivaroxaban 10 mg od with
enoxaparin 40 mg od or 30 mg bid, respectively, for 10–14 days (30,
31). In all four trials rivaroxaban was superior to the enoxaparin
regimens in terms of the primary efficacy outcome (composite of
any DVT, non-fatal PE, and all-cause mortality), without signifi-
cant differences in the rates of major bleeding (28–31). A pooled
analysis of the four RECORD studies indicated that rivaroxaban
regimens reduced symptomatic VTE plus all-cause mortality com-
pared with enoxaparin regimens; this finding was consistent across
patient subgroups, irrespective of age, gender, body mass index,
and renal function (32).
Apixaban was evaluated in three phase III clinical trials. In the
ADVANCE-1 study in TKR, apixaban (2.5 mg bid) for 10–14 days
did not meet the prespecified statistical criteria for non-inferiority
versus enoxaparin (30 mg bid) in terms of efficacy (composite of
any DVT, non-fatal PE, and all-cause mortality) (33). However, in
both ADVANCE-2 (TKR; 10–14 days) and ADVANCE-3 (THR; 35
days), apixaban 2.5 mg bid showed superior efficacy to enoxaparin
40 mg od (34, 35). In all three studies, there were no significant dif-
ferences in the rates of major bleeding between apixaban and enox-
aparin (33–35). A meta-analysis of ADVANCE-1, ADVANCE-2,
and a phase II study of apixaban in patients undergoing TKR sur-
gery showed that apixaban was more effective than enoxaparin in
reducing the risk of proximal DVT but no more effective in reduc-
ing the risk of PE or all-cause mortality (46).
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Dabigatran etexilate was evaluated in four phase III studies. Da-
bigatran etexilate (150 mg or 220 mg od) failed to show non-in-
feriority versus an enoxaparin regimen of 30 mg bid in terms of ef-
ficacy (composite of any DVT, symptomatic PE, and all-cause
mortality) in the RE-MOBILIZE study in TKR with a treatment
duration of 12–15 days (39). However, non-inferiority was dem-
onstrated versus an enoxaparin regimen of 40 mg od in RE-
MODEL (TKR; 6–10 days), RE-NOVATE, and RE-NOVATE II
(THR; 28–35 days), and there were no significant differences in the
rates of major bleeding (36–38). A meta-analysis of RE-MODEL,
RE-NOVATE and RE-MOBILIZE was performed by Wolowacz et
al., and the results of this were consistent with those of the individ-
ual studies.(47)
There was considerable variation in efficacy and safety out-
comes for rivaroxaban, apixaban, dabigatran etexilate and enox-
aparin across the studies described, reflecting differences in patient
populations, treatment regimens, and safety outcome definitions
(Table 2). Definitions of efficacy endpoints were similar for all
studies, and incidences of VTE were generally higher for patients
undergoing TKR rather than THR surgery (Table 2). Studies of
dabigatran etexilate generally showed higher incidences of VTE
than studies of rivaroxaban or apixaban for comparable indi-
cations.
Definitions of major bleeding varied across studies of rivar-
oxaban, apixaban, and dabigatran etexilate, confounding a direct
comparison of major bleeding rates between the three agents. No-
netheless, incidences of major bleeding were generally low across
all studies, with no clear separation between studies in patients
undergoing THR or TKR surgery (Table 2).
VTE prevention in hospitalised acutely ill
medical patients
Evidence suggests that VTE prophylaxis in hospitalised acutely ill
medical patients is under-used or used inappropriately (48–50).
The ENDORSE study found that only 6,119 (39.5%) of 15,487 en-
rolled acutely ill medical patients considered to be at risk of VTE
received appropriate thromboprophylaxis (51). In the IMPROVE
registry, approximately 60% of 15,156 patients classified as likely to
benefit from pharmacological prophylaxis received appropriate
prophylaxis (52). Other studies support these findings: the DVT
FREE study found that only 42% of the 2,726 hospitalised acutely
ill medical patients received thromboprophylaxis within the 30
days before DVT diagnosis (53); and in the CURVE study, al-
though 90% of the 1,702 hospitalised medically ill medical patients
had indications for thromboprophylaxis, only 16% received ap-
propriate medication (54).
The lack of consensus on the most appropriate duration of
thromboprophylaxis in acutely ill medical patients poses a chal-
lenge to clinicians. Several studies have assessed the benefits of
6–14 days (considered as the standard duration) of thrombopro-
phylaxis in acutely ill medical patients (6–8, 55, 56). MEDENOX
(prophylaxis in medical patients with enoxaparin) was a double-
blind, randomised, placebo-controlled study with 1,102 hospita-
lised patients who were >40 years of age and received enoxaparin
or placebo subcutaneously od for 6–14 days (7).ARTEMIS (fonda-
parinux for the prevention of VTE in older acutely ill medical pa-
tients) was a double-blind, randomised, placebo-controlled trial
that included 849 hospitalised medical patients aged ≥60 years who
were expected to remain in bed for at least four days and received
2.5 mg fondaparinux or placebo subcutaneously od for 6–14 days
Table 1: Summary of pharmacological profiles of apixaban, rivaroxaban and dabigatran etexilate.
Rivaroxaban (25) Apixaban (26) Dabigatran
etexilate (27)
Target Factor Xa Factor Xa Thrombin
Prodrug No No Yes
Bioavailability (%) ∼80 ∼50 6
Half-life, hours 5–13 ∼13 12–17
Time to peak, T
max
, hours 3 3–4 0.5–2.0
Renal elimination (%) 33 as unchanged drug;
33 as inactive metabolites
∼27 ∼85
Drug interactions* Potent inhibitors of both CYP3A4 and P-gp, CYP3A4 in-
ducers, anticoagulants, NSAIDs, platelet aggregation in-
hibitors
Potent inhibitors of
CYP3A4
Potent inhibitors or inducers of P-gp, anticoagulants,
NSAIDs, platelet aggregation inhibitors
Antidote None None None
Coagulation monitoring No No No
Dosing Once daily
†
Twice daily
‡
Once daily
§
*Clinically significant drug interactions.
†
Dosing approved in many countries (including the USA) for thromboprophylaxis after elective hip or knee replacement sur-
gery, and used in a study assessing rivaroxaban for thromboprophylaxis in medically ill patients (MAGELLAN).
‡
Dosing used in THR and TKR studies (ADVANCE-2
and ADVANCE-3) that met statistical non-inferiority criteria for apixaban versus enoxaparin, and used in a study assessing apixaban for thromboprophylaxis in
medically patients (ADOPT).
§
Dosing approved in several countries (not including the USA) for thromboprophylaxis after elective hip or knee replacement surgery.
CYP3A4, cytochrome P450 3A4; NSAID, non-steroidal anti-inflammatory drug; P-gp, P-glycoprotein; THR, total hip replacement; TKR, total knee replacement.
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(6). PREVENT (prospective evaluation of dalteparin efficacy for
prevention of VTE in immobilised patients) was an international,
multicentre, randomised, double-blind, placebo-controlled trial
that included 3,706 patients receiving subcutaneous dalteparin
5,000 IU daily or placebo for 14 days (8). These studies showed sig-
nificant reductions in VTE without a significant increase in the risk
of bleeding. However, this duration of thromboprophylaxis may
not provide adequate protection against VTE after hospital dis-
Table 2: Comparison of phase III studies of apixaban, rivaroxaban, and dabigatran etexilate for VTE prevention after total hip or knee replace-
ment surgery.
Study Comparison Primary efficacy outcome Main safety outcome
Rivaroxaban
RECORD1 Rivaroxaban 10 mg od vs. enoxaparin 40 mg
od (THR)
1.1% vs. 3.7%,
respectively; p<0.001 for superiority
0.3% vs. 0.1%,
respectively; p=0.18
RECORD2 Rivaroxaban 10 mg od vs. enoxaparin 40 mg
od (THR)
2.0% vs. 9.3%, respectively; p<0.0001 for
superiority
<0.1% vs. <0.1%, respectively
RECORD3 Rivaroxaban 10 mg od vs. enoxaparin 40 mg
od (TKR)
9.6% vs. 18.9%, respectively; p<0.001 for
superiority
0.6% vs. 0.5%,
respectively; p=0.77
RECORD4 Rivaroxaban 10 mg od vs. enoxaparin 30 mg
bid (TKR)
6.9% vs. 10.1%, respectively; p=0.0118 for
superiority
0.7% vs. 0.3%,
respectively; p=0.11
*
RECORD1–4 pooled
†
Rivaroxaban regimens vs. enoxaparin
regimens (THR and TKR)
Day 12 ± 2 active treatment period: 0.5%
vs. 1.0%, respectively; p=0.001
Total treatment period:
‡
0.6% vs. 1.3%, re-
spectively
Day 12 ± 2 active treatment period: 0.3%
vs. 0.2%, respectively; p=0.23
Total treatment period:
‡
0.4% vs. 0.2%, re-
spectively
Apixaban
ADVANCE-1 Apixaban 2.5 mg bid vs. enoxaparin 30 mg
bid (TKR)
Apixaban failed non-inferiority to enoxapa-
rin: 9.0% vs. 8.8%, respectively; p=0.06 for
non-inferiority
0.7% vs. 1.4%,
respectively; p=0.05
RE-NOVATE Dabigatran etexilate 150 mg od or 220 mg
od vs. enoxaparin 40 mg od (THR)
Both doses non-inferior to enoxaparin: 8.6%
(150 mg) and 6.0% (220 mg) vs. 6.7%, re-
spectively; p<0.0001 (150 mg), p<0.0001
(220 mg) (both for non-inferiority)
1.3% (150 mg) and 2.0% (220 mg) vs.
1.6%, respectively; p=0.60 (150 mg),
p=0.44 (220 mg)
RE-NOVATE II Dabigatran etexilate 220 mg od vs. enoxapa-
rin 40 mg od (THR)
Dabigatran non-inferior to enoxaparin: 7.7%
vs. 8.8%, respectively; p<0.0001 for non-in-
feriority
1.4% vs. 0.9%, respectively; p=0.40
RE-MOBILIZE Dabigatran etexilate 150 mg od or 220 mg
od vs. enoxaparin 30 mg bid (TKR)
Both doses failed non-inferiority to enoxapa-
rin: 33.7% (150 mg) and 31.1% (220 mg)
vs. 25.3%, respectively; p=0.0009 (150 mg),
p=0.0234 (220 mg)
0.6% (150 mg) and 0.6% (220 mg) vs.
1.4%, respectively
Dabigatran pooled
†
Dabigatran etexilate regimens vs. enoxaparin
(THR and TKR)
3.8% (150 mg) and 3.0% (220 mg) vs.
3.3%, respectively; p=0.91 (150 mg),
p=0.20 (220 mg)
1.1% (150 mg) and 1.4% (220 mg) vs.
1.4%, respectively; p=0.54 (150 mg),
p=0.19 (220 mg)
*p-value rounded up to two decimal points.
†
Both primary outcomes excluded asymptomatic events.
‡
Planned treatment period for double-blind study medication
for each RECORD study, including the placebo phase in RECORD2. bid, twice daily; DVT, deep-vein thrombosis; THR, total hip replacement; TKR, total knee replace-
ment; od, once daily; PE, pulmonary embolism.
ADVANCE-2 Apixaban 2.5 mg bid vs. enoxaparin 40 mg
od (TKR)
15.1% vs. 24.4%, respectively; p<0.0001
for non-inferiority and superiority
0.6% vs. 0.9%,
respectively; p=0.30
*
ADVANCE-3 Apixaban 2.5 mg bid vs. enoxaparin 40 mg
od (THR)
1.4% vs. 3.9%, respectively; p<0.001 for
non-inferiority and superiority
0.8% vs. 0.7%,
respectively; p=0.54
ADVANCE-1, AD-
VANCE-2, and phase II
study pooled
Apixaban regimens vs. enoxaparin regimens
(TKR)
Proximal DVT: 0.6% vs. 1.2%, respectively;
p=0.007
PE: 0.6% vs. 0.3%; p=0.055
0.6% vs. 1.2%,
respectively; p=0.034
Dabigatran etexilate
RE-MODEL Dabigatran etexilate 150 mg od or 220 mg
od vs. enoxaparin 40 mg od (TKR)
Both doses non-inferior to enoxaparin:
40.5% (150 mg) and 36.4% (220 mg) vs.
37.7%, respectively; p=0.82 (150 mg),
p=0.38 (220 mg)
1.3% (150 mg) and 1.5% (220 mg) vs.
1.3%, respectively; p=1.0 (150 mg), p=0.82
(220 mg)
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charge in at-risk acutely ill medical patients (20). In one study,
36.8% of patients developed VTE in the outpatient setting within
three months of hospitalisation (57). A recent study in 3,039 pa-
tients admitted to post-acute care facilities after medical disease or
surgery showed that 2.4% developed VTE within a median of 13
days, although 75.1% received thromboprophylaxis. Multivariate
Cox regression analysis identified previous VTE (hazard ratio
[HR] 5.67, 95% confidence interval [CI] 3.30–9.77; p<0.001) and
cancer (HR 2.26, 95% CI 1.36–3.75; p<0.01) as conditions that
were significantly associated with the occurrence of VTE (58).
The EXCLAIM study (extended prophylaxis for VTE in acutely
ill medical patients with prolonged immobilisation) aimed to de-
termine whether there was a benefit for extended-duration (28 ± 4
days) compared with standard-duration (10 ± 4 days) thrombo-
prophylaxis with enoxaparin 40 mg od. In this study, all patients
had previously received open-label enoxaparin for two weeks.
After randomisation to placebo for standard-duration therapy or
enoxaparin for extended-duration therapy, events were analysed
between day 10 and day 38. The inclusion criteria were hospitali-
sation for a medical illness, age ≥40 years, life expectancy of at least
six months, and reduced mobility level 1 (defined as total bed rest
or sedentary) or level 2 (defined as level 1 with bathroom privi-
leges; after interim analyses of efficacy and safety outcomes, the
definition of level 2 immobility was revised to include ≥1 risk fac-
tor for VTE, including age >75 years, previous VTE, and active or
previous cancer) (9). Analysis of the total patient population
found that extended-duration enoxaparin reduced the risk of VTE
when compared with placebo (2.5% vs. 4.0%, respectively; abso-
lute risk difference –1.53% [95% CI –2.54 to –0.52]). However, the
rate of major bleeding events was significantly higher in the ex-
tended-duration enoxaparin group versus the placebo group
(0.8% vs. 0.3%, respectively; absolute risk difference 0.51% [95%
CI 0.12–0.89]). Subgroup analyses found that the benefit of ex-
tended-duration enoxaparin was restricted to women, patients
>75 years of age, and those with mobility level 1.
Rivaroxaban has been evaluated in the MAGELLAN study: a
multicentre, randomised, parallel-group efficacy and safety study
for the prevention of VTE in hospitalised acutely ill medical pa-
tients that compared rivaroxaban with enoxaparin (10, 42). A total
of 8,101 patients were randomised to receive either subcutaneous
enoxaparin 40 mg od for 10 ± 4 days followed by placebo, or oral ri-
varoxaban 10 mg od for 35 ± 4 days. Patients were eligible if they
were hospitalised for an acute medical illness, aged ≥40 years, at
risk of VTE, and had a life expectancy of at least six months. Those
with acute infectious, inflammatory, or rheumatic diseases and
those with acute respiratory insufficiency were required to have at
least one additional risk factor for VTE (e.g. history of VTE or
cancer). The primary efficacy outcomes of this study were the
composite of asymptomatic proximal DVT, symptomatic DVT
(proximal or distal), symptomatic non-fatal PE, and VTE-related
death at day 10 + 5 (test for non-inferiority) or at day 35 + 6 (test for
superiority). Rivaroxaban was non-inferior in reducing risk of
VTE when compared with enoxaparin at day 10 (2.7% vs. 2.7%,
p=0.0025), but was superior at day 35 when compared with enox-
aparin followed by placebo (4.4% and 5.7% respectively;
p=0.0211). Clinically relevant bleeding, the composite of major
bleeding and non-major clinically relevant bleeding, was assessed
as the principal safety outcome. Overall rates of clinically relevant
bleeding were low, but were significantly higher in patients receiv-
ing rivaroxaban than in patients receiving enoxaparin (4.1% vs.
1.7% respectively, p<0.0001 for events between day 1 and day 35).
There were no significant differences in rates of other adverse
events including liver and cardiovascular events, and all-cause
mortality (10).
The double-blind, multicentre ADOPT study compared ex-
tended-duration (30 days) apixaban 2.5 mg bid with standard-du-
ration (6–14 days) enoxaparin 40 mg od (43). Patients were eligible
if they were ≥40 years of age and were hospitalised (expected stay of
at least three days) with congestive heart failure, respiratory failure,
or other medical disorders, and had at least one additional risk fac-
tor for VTE. A total of 6,528 patients were randomised, 4,495 of
whom were evaluated for the primary efficacy outcome, defined as
the 30-day composite of VTE-related death, PE, symptomatic DVT
(proximal or distal), or asymptomatic proximal-leg DVT as de-
tected by systematic bilateral compression ultrasonography. The
primary efficacy outcome occurred in 60 of 2,211 patients (2.71%)
of patients in the apixaban group and in 70 of 2,284 patients
(3.06%) in the enoxaparin group (relative risk [RR] with apixaban
0.87; 95% CI 0.62–1.23; p=0.44). The primary safety outcome was
major bleeding; during the 30-day treatment period, this outcome
occurred in 0.47% of patients receiving apixaban and in 0.19% of
patients receiving enoxaparin (RR 2.58; 95% CI 1.02–7.24;
p=0.04). Major plus non-major clinically relevant bleeding oc-
curred in 2.67% versus 2.08% of patients, respectively (RR 1.28;
95% CI 0.93–1.76).
The study designs of MAGELLAN and ADOPT were broadly
similar (10, 42, 43). The two studies both enrolled acutely ill medi-
cal patients at risk of VTE, had a comparator arm in common – en-
oxaparin 40 mg od for 10 ± 4 days (MAGELLAN) or 6–14 days
(ADOPT) – and evaluated extended-duration thromboprophyla-
xis. The primary efficacy outcome was also similarly defined for
the two studies. However, the outcomes of the studies differed; in
the MAGELLAN study, extended-duration rivaroxaban was
shown to be significantly more effective than standard-duration
enoxaparin for VTE prevention (10), whereas in ADOPT, ex-
tended-duration apixaban was shown to be not superior to enox-
aparin (43). In both studies the risk of bleeding was increased with
extended-duration regimens.
Most evidence for VTE prophylaxis in patients with cancer
comes from subgroup analyses of general surgery studies. There is
a need for studies of VTE prophylaxis in patients with cancer alone
that will differentiate between ambulatory and hospitalised cancer
patients. In one of the few investigations of ambulatory patients
with advanced cancer, the PROTECHT (PRophylaxis of Throm-
boEmbolism during CHemoTherapy) study showed that the
LMWH nadroparin given for the duration of chemotherapy up to
four months significantly reduced the incidence of thromboem-
bolic events compared with placebo (2.0% vs. 3.9%, respectively;
p=0.02), with no significant difference in the rates of major bleed-
ing events (59). Trials of the newer oral anticoagulants rivaroxaban
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(MAGELLAN study) and apixaban (ADOPT study) include pa-
tients with cancer, and subgroup analyses of these data will help to
increase our understanding of the potential role of new oral anti-
coagulants in VTE prevention in patients with cancer.
Discussion
The benefits of both short (after TKR) and extended (after THR
and HFS) pharmacological thromboprophylaxis after major or-
thopaedic surgery are well established and this is reflected in VTE
prevention guidelines (3). In hospitalised acutely ill medical pa-
tients at risk of VTE, clinical trials have shown that short-term
(6–14 days) thromboprophylaxis reduces the risk of VTE, al-
though the optimal duration of thromboprophylaxis in these pa-
tients is not known.
The average length of hospital stay for critical care, medical, and
surgical patients at risk of VTE is only 5.3 days (60), meaning that
patients who discontinue thromboprophylaxis when discharged
from hospital are at continued risk of VTE. Therefore, there is a
clinical need for anticoagulants that are effective and convenient to
use, particularly in the outpatient setting. In addition, from an
economic perspective, a reduction in VTE rates that is achieved by
using extended-duration prophylaxis compared with standard-
duration therapy in at-risk medical and surgical patients could be
more cost-effective (20, 61).
Despite the availability of effective anticoagulant therapies and
guideline recommendations, many patients (both surgical and
non-surgical) do not receive appropriate VTE prophylaxis in both
the inpatient and post-discharge settings (3, 60, 62, 63). One study
found that an estimated 36.8% of all at-risk patients did not receive
any thromboprophylaxis in hospital (60). Another study indicated
that 24.9% of patients after medical disease or surgery who were at
risk of VTE did not receive thromboprophylaxis in post-acute care
facilities, and in an additional study only 54.4% of orthopaedic
surgery patients had filled a prescription for thromboprophylaxis
30 days after discharge (58, 64). A reason for suboptimal thrombo-
prophylaxis in these patient groups may be the limitations of tradi-
tional anticoagulants, such as the need for daily subcutaneous in-
jections of UFH, LMWH, or fondaparinux – posing a particular
problem with compliance in the outpatient setting – or the
requirement for routine coagulation monitoring, or the presence
of food and drug interactions (65).
The newer oral anticoagulants – rivaroxaban, apixaban, and da-
bigatran etexilate – may have an advantage over parenteral agents,
particularly for patients who require prolonged thromboprophy-
laxis, because they can be administered orally as a fixed dose with-
out routine coagulation monitoring. These agents have demon-
strated superior efficacy for VTE prevention after THR or TKR
surgery without increasing the risk of bleeding (28–31, 34–37, 39).
In addition, both extended-duration rivaroxaban and apixaban
have been evaluated compared with standard-duration enoxapa-
rin for VTE prevention in hospitalised acutely ill medical patients;
rivaroxaban showed superior efficacy and apixaban showed simi-
lar efficacy to enoxaparin (10, 42, 43). Rivaroxaban, but not apixa-
ban, recorded a significant increase in the risk of clinically relevant
bleeding, compared with enoxaparin.
Most clinical data for the newer oral anticoagulants have dem-
onstrated equal or superior efficacy compared with LMWHs (66).
However, the risk of bleeding complications persists, reinforcing
the importance of evaluating the full benefit–risk profile of an
antithrombotic agent when considering its role in real-life clinical
practice (66).
The increased risk of bleeding observed in acutely ill medical
patients receiving extended thromboprophylaxis compared with
major orthopaedic surgery patients is likely a result of the differing
patient populations. Data from the IMPROVE registry identified
factors associated with increased bleeding risk in acutely ill pa-
tients; these factors include active gastroduodenal ulcer, prior
bleeding, and low platelet count. Risk factors for bleeding also in-
cluded increased age, hepatic or renal failure, intensive care unit
stay, central venous catheter, rheumatic disease, cancer, and male
gender (67). In comparison with hospitalised acutely ill medical
patients, patients undergoing elective major orthopaedic surgery
procedures are likely to be younger and fitter and therefore at re-
duced risk of bleeding events.
The characteristics of the newer oral anticoagulants may in-
crease adherence to thromboprophylaxis guidelines, thereby re-
ducing rates of VTE and consequently morbidity and mortality
(3). The evidence provided by the large randomised trials of these
newer oral anticoagulants is likely to contribute to updated guide-
lines and recommendations for VTE prevention in the future.
However, further research is still necessary in acutely ill medical
patients to determine if there are patient subgroups that might
benefit from extended thromboprophylaxis.
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